Compare Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) vs State Street SPDR S&P Biotech ETF — how do they compare? Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.94 (market cap $8.29B), while State Street SPDR S&P Biotech ETF trades at $154.13 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays a 4.82% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 0 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UGP | XBI | |
|---|---|---|
Market Cap | $8.29B | $10.11B |
Volume | 4,931,275 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $7.79 | $169.55 |
52-Week Low | $3.63 | $104.99 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $10.34B | — |
Dividend Yield | 4.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
